Conclusion
Our results indicated a potential feasibility of plasma SAP as a marker to approach PD.
Methods
In this study, we applied a proteomic strategy, by utilizing two-dimensional electrophoresis and mass spectrometry, to analyze two sample pools of plasma from the healthy individuals and PD subjects.
Results
IgGκL and human serum amyloid P component (SAP) were found differentially expressed between these pools. SAP level increased by approximately 5-fold in PD samples, and the ELISA procedure revealed a significant (P<0.001) increase in SAP concentration (65.9 ± 18.7μg/mL) in the plasma of PD subjects (healthy individuals, 35.0 ± 12.5μg/mL), with sensitivity of 94.1% and specificity of 87.5%.